Amgen (AMGN) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Amgen is set to release its Q2 2025 earnings results on August 5th, with analysts expecting earnings of $5.21 per share and revenue of $8.86 billion.
• The company's last earnings report showed a 9.4% year-over-year revenue increase to $8.15 billion, beating estimates by $0.10.
• Amgen's stock recently opened at $301.29 and has a market capitalization of $162.01 billion, with a consensus rating of "Hold" from analysts.

Amgen (NASDAQ:AMGN - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 5th. Analysts expect Amgen to post earnings of $5.21 per share and revenue of $8.86 billion for the quarter.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same quarter in the previous year, the firm earned $3.96 EPS. Amgen's quarterly revenue was up 9.4% on a year-over-year basis. On average, analysts expect Amgen to post $21 EPS for the current fiscal year and $21 EPS for the next fiscal year.

Amgen Price Performance

AMGN traded up $2.28 during trading on Friday, hitting $297.38. The company's stock had a trading volume of 1,352,993 shares, compared to its average volume of 2,902,211. The firm's 50 day moving average price is $291.53 and its two-hundred day moving average price is $291.66. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 8.70. Amgen has a 12 month low of $253.30 and a 12 month high of $339.17. The stock has a market capitalization of $159.90 billion, a price-to-earnings ratio of 27.13, a price-to-earnings-growth ratio of 2.61 and a beta of 0.49.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of the company's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president owned 8,162 shares in the company, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.76% of the stock is owned by insiders.

Hedge Funds Weigh In On Amgen

A hedge fund recently raised its stake in Amgen stock. Brighton Jones LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 23.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,468 shares of the medical research company's stock after acquiring an additional 5,226 shares during the quarter. Brighton Jones LLC's holdings in Amgen were worth $7,159,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 76.50% of the company's stock.

Analysts Set New Price Targets

AMGN has been the subject of several research analyst reports. Guggenheim initiated coverage on Amgen in a research report on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 price objective for the company. Royal Bank Of Canada dropped their price target on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Wall Street Zen raised shares of Amgen from a "buy" rating to a "strong-buy" rating in a research note on Sunday, May 18th. Morgan Stanley reissued an "equal weight" rating on shares of Amgen in a research note on Friday, May 2nd. Finally, Erste Group Bank downgraded shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $307.27.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.